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Abstract
Background: Rates of mother-to-child transmission of HIV-1 (MTCT) have historically been
lower in European than in American cohort studies, possibly due to differences in population
characteristics. The Pediatric AIDS Clinical Trials Group Protocol (PACTG) 316 trial evaluated the
effectiveness of the addition of intrapartum/neonatal nevirapine in reducing MTCT in women
already receiving antiretroviral prophylaxis. Participation of large numbers of pregnant HIV-infected
women from the US and Western Europe enrolling in the same clinical trial provided the
opportunity to identify and explore differences in their characteristics and in the use of non-study
interventions to reduce MTCT.
Methods: In this secondary analysis, 1350 women were categorized according to enrollment in
centres in the USA (n = 978) or in Europe (n = 372). Factors associated with receipt of highly active
antiretroviral therapy and with elective caesarean delivery were identified with logistic regression.
Results: In Europe, women enrolled were more likely to be white and those of black race were
mainly born in Sub-Saharan Africa. Women in the US were younger and more likely to have
previous pregnancies and miscarriages and a history of sexually transmitted infections.
More than 90% of women did not report symptoms of their HIV infection; however, more women
from the US had symptoms (8%), compared to women from Europe (4%). Women in the US were
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less likely to have HIV RNA levels <400 copies/ml at delivery than women enrolling in Europe, and
more likely to receive highly active antiretroviral therapy, and to start therapy earlier in pregnancy.
The elective caesarean delivery rate in Europe was 61%, significantly higher than that in the US
(22%). Overall, 1.48% of infants were infected and there was no significant difference in the rate of
transmission between Europe and the US despite the different approaches to treatment and
delivery.
Conclusion: These findings confirm that there are important historical differences between the
HIV-infected pregnant populations in Western Europe and the USA, both in terms of the
characteristics of the women and their obstetric and therapeutic management. Although highly
active antiretroviral therapy predominates in pregnancy in both settings now, population
differences are likely to remain.
Trial registration: NCT00000869
Background
Rates of mother-to-child transmission of HIV-1 (MTCT)
have historically been lower in European than in Ameri-
can cohort studies [1-8]. It has been suggested that this
was likely to be related to differences in population char-
acteristics [9,10]. Although in the 1980s and early 1990s
the HIV epidemic among pregnant women in Europe was
mainly associated with injecting drug use (IDU) [11,12],
since the mid-1990s there has been a shift towards heter-
osexually-acquired HIV, largely in women of sub-Saharan
origin [12,13]. Generally, health care services and in par-
ticular antenatal care is readily available to these popula-
tions in Western Europe. In the USA, there has been a
similar trend, with heterosexual acquisition overtaking
IDU as the main transmission category among women
with AIDS in 1995 [14]; in 2004, 78% of HIV infections
among women were due to heterosexual contact, 20% to
IDU and 2% to other routes [14]. Differences in health
care provision and standards of care may have led to dif-
ferences between these two geographical regions in the
availability and uptake of various interventions available
for HIV infected pregnant women [15-19].
The PACTG 316 trial was a placebo-controlled ran-
domised trial to evaluate the additional value of single
dose nevirapine (sdNVP) at delivery in reducing MTCT in
women already receiving antiretroviral prophylaxis [20].
The trial was initiated in the USA in 1997 and extended
through collaboration with two large ongoing European
perinatal cohort studies, the French Perinatal Cohort
Study (ANRS 083) and the European Collaborative Study
[21]. The trial was stopped prematurely in June 2000 after
the results of a planned interim analysis indicated a lower
than anticipated overall MTCT rate (1.5%), without a sig-
nificant difference between the sdNVP and the placebo
arms [20].
We here take the opportunity to identify and explore dif-
ferences in the characteristics of HIV infected pregnant
women enrolling in the trial, and in the use of interven-
tions to reduce MTCT between Europe and USA, in partic-
ular, the use of highly active antiretroviral therapy
(HAART) and elective caesarean delivery.
Methods
The PACTG 316 trial was initiated in the United States
(including Puerto Rico) in May, 1997. Between May 1997
and June 2000, centres collaborating in France, Italy,
Spain, Sweden, UK, Belgium, Germany, Switzerland, Hol-
land, Denmark, Bahamas and Brazil were invited to join
the PACTG 316 trial. The methods of this randomized,
blinded trial have been fully described elsewhere [20]. In
brief, HIV-infected pregnant women were initially
enrolled in the trial after 28 weeks of gestation (later
reduced to 20 weeks), with written informed consent.
They were randomised to receive either oral nevirapine
(200 mg at onset of labour) or placebo; their infants
received the same study drug (infant 2 mg/kg oral nevirap-
ine or placebo) 48–72 hours after birth. All clinicians were
encouraged to offer all HIV-infected pregnant women at
least a regimen of prophylactic zidovudine monotherapy
in line with the ACTG 076 protocol [22]. Women were
allowed to receive any combination of licensed antiretro-
viral drugs in pregnancy as prescribed by their clinician,
with the exception of non-nucleoside reverse transcriptase
inhibitors.
In all participating centres, HIV-infected women were sys-
tematically identified during pregnancy, according to
local practice. At enrolment, baseline information includ-
ing socio-demographic characteristics, obstetric history,
history of and current use of antiretroviral therapy (ART),
results from screening for sexually transmitted infections
(STI) (gonorrhea, chlamydia, human papilloma virus,
herpes simplex, syphilis and trichomonas vaginalis) and
clinical history were collected using standardized forms.
Clinical and laboratory evaluations, including CD4 lym-
phocyte count and HIV RNA quantification were carried
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out at enrolment, delivery and post-partum. CD4 counts
and viral load measurements were carried out locally in
laboratories which were certified by ACTG or other
regional quality assurance programme. Infants had clini-
cal and laboratory information collected at birth, and sub-
sequently according to the protocol.
Definitions
In this analysis, we compared all mother-child pairs
enrolled in the European centres participating in the trial
with those enrolled in the sites in the USA and Puerto
Rico. Mode of acquisition of HIV infection was assessed
on the basis of self-report; no illicit drug screening was
carried out. Gestational age was estimated with ultra-
sound performed at less than 20 weeks gestation or use of
date of last menstrual period that corresponded with uter-
ine size. Caesarean deliveries taking place before the onset
of labour and before rupture of membranes were classi-
fied as elective caesarean deliveries, with all other caesar-
ean deliveries classified as emergency procedures
regardless of indication. Low birth weight was defined as
birth weight <2500 g. Classification of type of antenatal
ART was on the basis of the most potent therapy received.
ART was classified as monotherapy if a single nucleoside
was administered at a time, as dual therapy if any two
nucleosides were administered and as HAART if a protease
inhibitor plus two other drugs (excluding NNRTIs as this
was an exclusion criteria for the trial) were administered.
Undetectable viral load was defined as having HIV RNA
levels below 400 copies/ml. Symptomatic HIV disease was
defined as being in the Centers for Disease Control (CDC)
disease category B and C.
Statistical analysis
For univariate comparisons among women between
Europe and USA, two-sided tests were performed using χ2
test or Fisher exact tests for discrete outcomes, and Wil-
coxon test for continuous outcomes. For the multivariate
comparisons, logistic regression analysis was used to
obtain odds ratios (OR), adjusted odds ratios (AOR) and
95% confidence intervals (95% CI). Statistical software
SAS (SAS Institute, Cary, North Carolina, USA) was used
for the statistical analysis.
Results
A total of 1350 women enrolled in the trial had delivered
by the time the trial was stopped, 978 (72%) from the
USA and 372 (28%) from Europe. Table 1 presents socio-
demographic and most likely mode of acquisition of HIV
infection by continent. There was a significantly higher
proportion of white women in the European centres than
in the USA. Nearly half of the women from European cen-
tres were black; most had been born in sub-Saharan
Africa. As Table 1 shows, there were significant differences
between the two populations with regard to history of
reproductive health, with women in the USA having a
higher prevalence of previous miscarriages (28% versus
13%) and higher parity compared to those in Europe,
who had a higher prevalence of history of pregnancy ter-
mination (48% versus 27% in the USA). Substantially and
significantly fewer women enrolling in Europe had a his-
tory of STI compared with those in the USA.
In terms of HIV-related characteristics, although there
were no significant differences between continents with
regard to immunological status at study entry and at deliv-
ery, women from the USA were more likely to have symp-
tomatic HIV disease (Table 2). Very similar proportions in
the two settings had HIV RNA levels below 400 copies/ml
at study entry; however, by the time of delivery there was
a significant difference between geographic areas, with
fewer women in the US having HIV RNA below 400 cop-
ies/ml and an overall higher median in the US versus
Europe. In a sub-analysis of the 259 women from Euro-
pean and the 539 women from USA sites who had been
diagnosed with HIV infection prior to their current preg-
nancy, almost identical proportions (182/259, 70% and
357/539, 66%) were already receiving ART at enrolment.
Among the 606 women in the USA who started ART in
pregnancy, the median gestational age at initiation was 18
weeks (range, 14–25 weeks), substantially earlier than the
median of 27 weeks (range 18–32) among the 190
women in Europe starting therapy antenatally.
Median gestational age at delivery was 38.4 weeks (37.3–
39.6) and 38.1 weeks (37.1–39.0), and median birth
weight was 3077 g and 3020 g in the USA and Europe,
respectively. The prevalence of low birth weight was simi-
lar in both continents, at 12% in the US (n = 122) and
14% in Europe (n = 54). Mode of delivery varied signifi-
cantly by geographic area (p < 0.0001). In the USA, the
elective caesarean delivery rate was 22% (n = 212), the
emergency caesarean delivery rate was 17% (n = 169) and
the vaginal delivery rate was 61% (n = 597); respective
rates in Europe were 61% (n = 228), 18% (n = 65) and
21% (n = 79).
Subsequent analyses focused on geographic differences in
the use of HAART in pregnancy and of elective caesarean
delivery. Table 3 presents the results of univariable and
multivariable logistic regression analyses to identify fac-
tors associated with likelihood of receiving HAART in
pregnancy. Univariably, geographic area, low CD4 count
and undetectable viral load at entry and at delivery were
associated with receipt of HAART. In analyses adjusting
for ethnicity, mode of delivery and immunological and
virological status, women from the USA were nearly twice
as likely to receive HAART as women from Europe, whilst
those with CD4 counts ≥ 400 cells/ml and detectable viral
load at trial entry were significantly less likely to receive
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HAART in pregnancy. Stratified analyses for the two geo-
graphic areas identified the same risk factors, with odds
ratios of similar magnitudes.
In addition to use of antiretroviral drugs in pregnancy and
avoidance of breastfeeding, elective caesarean delivery is
the other key PMTCT intervention. Further logistic regres-
sions were therefore carried out for likelihood of having
an elective caesarean versus other delivery modes (emer-
gency caesarean or vaginal delivery) (Table 4). Delivery in
centres in the USA was associated with an adjusted 82%
reduced odds of elective caesarean delivery compared
with delivery in Europe. Black women were 33% less
likely to deliver by elective caesarean than white women,
and those receiving two or more antiretroviral drugs ante-
natally were less likely to have an elective caesarean deliv-
ery compared with women receiving monotherapy or no
ART (Table 4). As there were distinct differences between
the continents regarding many of these explanatory varia-
bles (Tables 1 and 2), stratified analyses were carried out
for each geographic area separately. Among the women
from the USA, none of the explanatory variables in Table
3 were associated with elective caesarean delivery univari-
ably [data not shown]. In Europe, black versus white eth-
nicity was associated with a reduced likelihood of elective
caesarean, with borderline significance (AOR 0.65, 95%
CI 0.42–0.99, p = 0.048), and dual therapy and HAART
with around a two-thirds reduced likelihood of elective
Table 1: Characteristics of HIV-infected pregnant women in PACTG 316, USA versus Europe
Characteristics USA Europe Total p-value*
Total mothers delivered 978 372 1350
Median age: entry (IQR) 27.2 (22.9–31.8) 30 (26.9–34) 28.1 (23.9–32.4) <0.0001
Ethnicity <0.0001
White 119 (12%) 190 (51%) 309 (23%)
Black 621 (64%) 172 (46%) 793 (59%)
Hispanic 223 (23%) 8 (2%) 231 (17%)
Other 15 (1.5%) 2 (0.5%) 17 (1%)
Parity 0.0001
0–1 161 (17%) 80 (22%) 241 (18%)
2–3 399 (41%) 168 (45%) 567 (42%)
4–5 267 (27%) 97 (26%) 364 (27%)
≥6 151 (15%) 27 (7%) 178 (13%)
Previous miscarriages <0.0001
0 707 (72%) 325 (87%) 1032 (76%)
1–2 247 (25%) 44 (12%) 291 (22%)
3–6 24 (2.5%) 3 (1%) 27 (2%)
Previous terminations <0.0001
0 710 (73%) 192 (52%) 902 (67%)
1–2 220 (22%) 149 (40%) 369 (27%)
3–4 41 (4%) 28 (7%) 69 (5%)
5–12 7 (1%) 3 (1%) 10 (1%)
Timing of HIV diagnosis <0.0001
Pre-pregnancy 539 (55%) 259 (70%) 798 (59%)
Antenatal 439 (45%) 112 (30%) 551 (41%)
Mode of acquisition#
Sexual with HIV at risk 336 (34%) 44 (12%) 380 (28%) <0.0001
Sexual with HIV positive 214 (22%) 105 (28%) 319 (24%) 0.0623
Sexual with HIV unknown 716 (73%) 162 (44%) 878 (65%) <0.0001
Current IDU 12 (1%) 11 (3%) 23 (2%) 0.0331
Previous IDU 68 (7%) 35 (9%) 103 (8%) 0.1340
Blood transfusion 20 (2%) 7 (2%) 27 (2%) 0.9999
Occupational risk 22 (2%) 3 (1%) 25 (2%) 0.1108
Other risk factor 44 (4%) 8 (2%) 52 (4%) <0.0001
Unknown risk factor 47 (5%) 46 (12%) 93 (7%) 0.0401
STD history <0.0001
Yes 280 (29%) 19 (5%) 299 (22%)
No 450 (46%) 353 (95%) 803 (60%)
Unknown 248 (25%) 0 (0) 248 (18%)
# Some women reported multiple risk factors
* for the difference USA versus Europe
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caesarean versus no therapy or monotherapy (AORs 0.35
[0.21–0.60] p < 0.0001; 0.41 [0.24–0.72] p = 0.0015
respectively).
The primary outcome measure of the PACTG 316 trial was
detection of HIV infection in the infants. Overall there was
a very low rate of MTCT at 1.48% [95% CI 0.91–2.28] (20
vertical transmissions; USA 1.64% [95% CI 0.94–2.64]
and Europe 1.08% [0.29–2.73]).
Discussion
There were distinct differences between the HIV-infected
pregnant women enrolling in the PACTG 316 trial in the
USA (accounting for nearly three-quarters of the total
mother-child pairs in the trial) compared with the Euro-
pean centres. Black women of African-American ethnicity
predominated in the US setting, with a further quarter of
the women enrolling of Hispanic ethnicity, and only 12%
being non-Hispanic white. Those recruited in Europe were
almost equally divided between white European and non-
white women, the vast majority of whom were of African
origin who had arrived in Europe as asylum-seekers, refu-
gees or migrants. These ethnic patterns are consistent with
what is known about the epidemiology of HIV infection
in pregnancy in the USA and in Europe [13,16,23].
Substantially more women from the European sites had
been diagnosed with HIV prior to their current pregnancy
than in the USA. Today, most identified HIV-infected
women of child-bearing age are most likely diagnosed
either as a result of antenatal testing or through more tar-
geted testing of specific risk groups, such as injecting drug
users or attenders of STD clinics. Parity was somewhat
higher among the US women. Although there was a signif-
icantly higher prevalence of active IDU in Europe, this was
only 3% in this setting. On the basis of these findings, the
lower ascertainment of infection status among the US
women before entry may reflect poorer access to or uptake
of antenatal HIV testing in prior pregnancies or of HIV
testing outside antenatal care, or alternatively, the possi-
bility that the women from the USA acquired their HIV
infection more recently (i.e. since a previous pregnancy),
which is consistent with their younger age compared with
the women from European sites, and their somewhat
higher CD4 count at entry.
In terms of reproductive health, the HIV-infected women
in the USA had a significantly higher prevalence of previ-
ous miscarriages than in Europe, double that in Europe,
which may reflect a variety of factors including possible
geographic/cultural differences with regard to reporting
Table 2: Characteristics of HIV infected pregnant women, USA versus Europe: disease progression and treatment
Characteristic USA Europe Overall P-value
Median CD4 count: entry (IQR) 437 (293–600) 420 (299–568) 430 (294–592) 0.6958
<200 cells per ml 124 (13%) 37 (10%) 161 (12%)
200–499 294 (30%) 132 (35%) 426 (32%)
≥500 560 (57%) 203 (55%) 763 (57%)
Median HIV RNA: entry (IQR) 581 (274–3635) 700 (200–4740) 594 (243–3845) 0.1225
≤400 copies/ml 424 (43%) 142 (38%) 566 (42%)
400–2,499 252 (26%) 92 (24%) 344 (25%)
2,500–10,000 143 (15%) 62 (17%) 205 (15%)
>10,000 138 (14%) 57 (15%) 195 (14%)
Median CD4 count: delivery (IQR) 480 (308–658) 444 (320–632) 469 (310–653) 0.6849
<200 cells/ml 103 (12%) 26 (8%) 129 (11%)
200–499 233 (27%) 109 (34%) 342 (29%)
≥500 531 (61%) 187 (58%) 718 (60%)
Median HIV RNA: delivery (IQR) 405 (237–2638) 200 (68–1300) 400 (200–2300) 0.0001
≤400 copies/ml 450 (50%) 176 (64%) 626 (53%)
400–2,499 220 (24%) 49 (18%) 269 (23%)
2,500–10,000 115 (13%) 36 (14%) 151 (13%)
>10,000 116 (13%) 16 (6%) 132 (11%)
Maternal ARV use <0.0001
HAART 448 (46%) 119 (32%) 567 (42%)
Dual therapy 342 (35%) 132 (35%) 474 (35%)
Monotherapy 182 (19%) 119 (32%) 301 (22%)
No ARV 6 (0.6%) 2 (0.5%) 8 (0.6%)
Timing of ARV initiation 0.0001
Pre-pregnancy 357 (37%) 182 (49%) 539 (40%)
During pregnancy 606 (63%) 190 (51%) 796 (60%)
Symptomatic HIV disease at entry 0.0194
Yes 74 (8%) 15 (4%) 89 (7%)
No 904 (92%) 357 (96%) 1261 (93%)
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Table 3: Factors associated with antenatal HAART use
N (%) OR (95% CI) AOR (95% CI) p-value
Ethnicity
White 309 (23) 1.0 1.0
Black 793 (59) 1.06 (0.82, 1.39) 0.84 (0.62, 1.13) 0.2470
Other 248 (18) 1.15 (0.82, 1.62) 0.96 (0.66, 1.39) 0.8374
Geographic area
Europe 372 (28) 1.0 1.0
USA 978 (72) 1.79 (1.39, 2.30) 1.82 (1.40, 2.38) <0.0001
Mode of delivery
Vaginal delivery or non-elective caesarean 910 (67) 1.0 1.0
Elective caesarean 440 (33) 0.80 (0.64, 1.01) 0.99 (0.76, 1.28) 0.9366
CD4 count (entry)
< 400 cells per ml 586 (43) 1.0 1.0
≥400 cells per ml 764 (57) 0.43 (0.35, 0.54) 0.36 (0.28, 0.46) <0.0001
CD4 count (delivery)
< 400 cells per ml 543 (40) 1.0 1.0
≥400 cells per ml 807 (60) 0.49 (0.40, 0.62) 0.76 (0.56, 1.03) 0.0757
Viral load (entry)
Undetectable 570 (44) 1.00 1.0
Detectable 740 (56) 0.58 (0.46, 0.72) 0.48 (0.38, 0.61) <0.0001
Viral load (delivery)
Undetectable 626 (53) 1.0 1.0
Detectable 555 (47) 0.79 (0.62, 0.99) 0.97 (0.71, 1.31) 0.8197
Table 4: Factors associated with likelihood of delivery by elective caesarean
N (%) OR (95% CI) AOR (95% CI) p-value
Ethnicity
White 309 (23) 1.0 1.0
Black 793 (59) 0.41 (0.31, 0.53) 0.67 (0.49, 0.91) 0.0107
Other 248 (18) 0.40 (0.28, 0.57) 0.89 (0.60, 1.32) 0.5490
Geographic area
Europe 372 (28) 1.0 1.0
USA 978 (72) 0.18 (0.14, 0.23) 0.18 (0.14, 0.24) 0.0001
Antenatal ART
None/monotherapy 309 (23) 1.0 1.0
Dual therapy 474 (35) 0.51 (0.38, 0.69) 0.57 (0.41, 0.78) 0.0006
HAART 567 (42) 0.54 (0.41, 0.72) 0.70 (0.52, 0.96) 0.0263
CD4 count (entry)
< 400 cells per ml 586 (43) 1.0 1.0
≥400 cells per ml 764 (57) 1.06 (0.84, 1.33) 1.08 (0.84, 1.39) 0.5371
CD4 count (delivery)
< 400 cells per ml 543 (40) 1.0 1.0
≥400 cells per ml 807 (60) 1.04 (0.83, 1.31) 1.10 (0.86, 1.42) 0.4486
Viral load (entry)
Undetectable 570 (44) 1.00 1.0
Detectable 740 (56) 0.97 (0.77, 1.23) 0.83 (0.65, 1.07) 0.1571
Viral load (delivery)
Undetectable 626 (53) 1.0 1.0
Detectable 555 (47) 0.82 (0.64, 1.05) 0.90 (0.69, 1.17) 0.4308
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prior miscarriage as this was a self-reported variable.
Although the women recruited in the US were younger
than those enrolled in Europe, they had a higher parity
than their European counterparts, whilst women from
Europe had a significantly higher pregnancy termination
rate; these findings may not only reflect cultural differ-
ences, but also access to reproductive care services [24].
The PACTG 316 trial spanned an important and dynamic
era with regard to use of ART in pregnancy, both for
maternal health and for preventing MTCT. Our findings
reflect regional differences in use of combination ART,
with more rapid uptake in the USA than in Europe
[19,25,26]. In the Women and Infants Transmission
Study, based in the USA and Puerto Rico, half of the preg-
nant women enrolled by 1998 were receiving HAART,
increasing to more than 60% in 1999–2000 [27]. In
Europe, although there was a steadily increasing uptake of
combination therapy in pregnancy, in the absence of a
randomised trial to show the efficacy of HAART in preven-
tion of MTCT, some clinicians showed caution regarding
prescribing HAART for women without symptomatic HIV
disease, preferring to continue using the combination of
zidovudine monotherapy according to the 076 regimen,
elective caesarean delivery and avoidance of breastfeeding
[28-31].
These parallel situations are apparent in the geographic
differences seen here, with significantly more HAART use
in the USA versus more monotherapy use in Europe.
However, these differences are largely historical, and
HAART now predominates in the treatment of pregnant
women in Europe [32,33]. A fifth of women in Europe
received the dual combination of zidovudine and lamivu-
dine in pregnancy (data not shown); this partly reflects
ongoing research in France at the time [34]. Furthermore,
the lower prevalence of HAART use in European women
may also reflect the non-eligibility of those women on
HAART due to prior or current use of NVP-containing
HAART, which was a popular regimen in Europe at the
time [28]. Although the enrolled women from the US and
Europe had similar CD4 counts and viral loads at entry,
the US women had double the prevalence of symptomatic
disease at entry (although this was low overall in both
areas) and were less likely to have been diagnosed with
HIV infection before the current pregnancy or to already
be on ART at the time they became pregnant. Overall,
60% of women started ART for the first time in pregnancy
and antenatal ART initiation was significantly earlier in
the US than in Europe (18 weeks versus 27 weeks), prob-
ably reflecting timing of HIV diagnosis and/or manage-
ment differences. By the time of delivery, although the
two geographic groups remained immunologically simi-
lar, women from the USA were significantly less likely to
have undetectable viral loads at delivery compared with
women delivering in Europe, despite more women from
the US receiving earlier and/or more potent ART. How-
ever, MTCT rates were similar between continents. In a
previous analysis focused on women in the US sites of the
PACTG 316 trial, black women (accounting for nearly
two-thirds of the women enrolled) were significantly less
likely to achieve undetectable viral loads by delivery than
white women [35].
There was a considerably lower elective caesarean rate
among the women delivering in the USA than in Europe,
at 22% versus 61%. None of the explanatory variables
(ethnicity, ART, maternal CD4 count or viral load) pre-
dicted likelihood of elective caesarean delivery among
women from the USA. This is consistent with an individ-
ualised approach to elective caesarean delivery in this set-
ting among HIV-infected women, with those with
obstetric indications for elective caesarean most likely to
constitute the majority of the elective caesarean group
[36,37].
In Europe, guidelines current during the trial recom-
mended universal offer of elective caesarean delivery to
prevent MTCT [38-40]. However, as indicated by the sub-
analysis of European women, receipt of HAART was asso-
ciated with a significantly lower likelihood of having an
elective caesarean delivery. This reflects the growing
uncertainty from this time of the added benefit of elective
caesarean delivery for women with undetectable plasma
HIV RNA loads, and specifically concerns that the poten-
tial benefits in terms of reduced MTCT risk may be out-
weighed by the costs, such as the increased risk of post-
partum complications and greater burden on health care
services associated with elective caesarean delivery. This
lack of consensus has continued in the absence of a defin-
itive answer, with current policy and practice regarding
mode of delivery varying considerably across Europe,
although an increasing number of policies now recom-
mend offering a vaginal delivery to women on successful
HAART with undetectable viral load [41].
Concerns exist regarding the generalizability of results
from HIV clinical trials, particularly those with stringent
inclusion and exclusion criteria [42-44]. The PACTG 316
trial was designed with broad inclusion criteria, although
the exclusion criteria of previous NNRTI-use may limit the
generalizability of specific results here, as discussed above.
Conclusion
These findings confirm that there are important historical
differences between the HIV-infected pregnant popula-
tions in Western Europe and the USA, both in terms of the
characteristics of the women and their obstetric and ther-
apeutic management. Although the therapeutic manage-
ment of pregnant HIV-infected women is now more
BMC Infectious Diseases 2007, 7:60 http://www.biomedcentral.com/1471-2334/7/60
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uniform between the continents, with the predominance
of HAART initiated from before or during pregnancy, sig-
nificant population differences are likely to remain. This
is of importance in interpreting results from previous
research and in the design of future studies.
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